VP22-mediated and light-activated delivery of an anti-c-raf1 antisense oligonucleotide improves its activity after intratumoral injection in nude mice
Authors:
- Nadia NormandNNNadia Normand
- Neil BrewisNBNeil Brewis
- Peter O'HArePOPeter O'HAre
- Marie-Christine FavrotMFMarie-Christine Favrot
- Jean-Luc CollJean-Luc Coll
Open Access
- 1 November 2003
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 8 (5) , 840-845
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Particle assembly incorporating a VP22–BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosisMolecular Therapy, 2003
- Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion proteinGene Therapy, 2003
- Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumorsGastroenterology, 2002
- Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion geneGene Therapy, 2001
- Antisense therapy in oncology: new hope for an old idea?The Lancet, 2001
- Particle Formation by a Conserved Domain of the Herpes Simplex Virus Protein VP22 Facilitating Protein and Nucleic Acid DeliveryJournal of Biological Chemistry, 2001
- Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22Gene Therapy, 1999
- Intercellular delivery of functional p53 by the herpesvirus protein VP22Nature Biotechnology, 1998
- Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural ProteinCell, 1997
- Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic AcidNature, 1974